Indaptus Therapeutics Inc... (INDP)
0.52
-0.03 (-5.44%)
At close: Apr 01, 2025, 3:55 PM
0.55
6.37%
After-hours: Apr 01, 2025, 07:50 PM EDT
-5.44% (1D)
| Bid | 0.5 |
| Market Cap | 7.43M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.17M |
| EPS (ttm) | -1.61 |
| PE Ratio (ttm) | -0.32 |
| Forward PE | -0.65 |
| Analyst | Buy |
| Ask | 0.63 |
| Volume | 73,292 |
| Avg. Volume (20D) | 420,771 |
| Open | 0.54 |
| Previous Close | 0.55 |
| Day's Range | 0.51 - 0.55 |
| 52-Week Range | 0.51 - 3.10 |
| Beta | 1.11 |
About INDP
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was fo...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 4, 2015
Employees 7
Stock Exchange NASDAQ
Ticker Symbol INDP
Website https://indaptusrx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for INDP stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 1550.49% from the latest price.
Stock Forecasts4 months ago
-4.76%
Indaptus Therapeutics shares are trading lower. Th...
Unlock content with
Pro Subscription
5 months ago
+12.6%
Indaptus Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.
